Welcome to our dedicated page for Takeda Pharm SEC filings (Ticker: TAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Takeda Pharmaceutical Company Limited American Depositary Shares (NYSE: TAK) on Stock Titan provides access to the company’s U.S. regulatory disclosures, primarily furnished on Form 20-F and Form 6-K as a foreign private issuer. Takeda prepares its consolidated financial statements in accordance with International Financial Reporting Standards (IFRS) and uses these filings to report semi-annual and annual results, management guidance and material developments in its business.
Recent Form 6-K submissions include English translations of Takeda’s semi-annual securities report and earnings report (Kessan Tanshin) for the six-month period ended September 30, 2025. These documents present revenue by business area (Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology, Vaccines, Neuroscience and Other) and by geographic region, along with operating profit, net profit, cash flow information and explanations of non-IFRS core measures such as core revenue, core operating profit and core EPS. They also discuss factors affecting performance, including generic erosion of specific products, foreign exchange impacts and changes in product mix.
Takeda’s 6-K filings additionally furnish press releases that describe key R&D and strategic events, such as Phase 3 data for zasocitinib (TAK-279) in plaque psoriasis, longer-term VERIFY and THRIVE results for rusfertide in polycythemia vera, portfolio decisions like discontinuation of cell therapy efforts, and revised forecasts for FY2025 revenue and profit. These exhibits provide context on how clinical outcomes, impairments of intangible assets and strategic partnerships influence Takeda’s financial outlook.
Through Stock Titan, users can review Takeda’s SEC filings as they are posted, while AI-powered tools can help summarize lengthy IFRS financial reports, highlight changes in management guidance, and surface important disclosures related to pipeline programs, impairments, capital allocation and regional performance. This makes it easier to understand how Takeda’s global biopharmaceutical operations and late-stage pipeline are reflected in its official U.S. regulatory documents.
Takeda Pharmaceutical Company Limited reports that its Board of Directors approved a reversal of general reserve and other voluntary reserves on September 24, 2025. The company is decreasing several surplus items, including a general reserve of JPY 814,500 million and specific reserves for retirement benefits (JPY 5,000 million), dividends (JPY 11,000 million), research and development (JPY 2,400 million), capital improvements (JPY 1,054 million) and promotion of exports (JPY 434 million). These amounts, totaling JPY 834,388 million, are being reclassified as unappropriated retained earnings on Takeda’s unconsolidated balance sheet. The stated purpose is to enable a flexible capital policy by better using internal reserves that had remained unused for many years. The company states that this reclassification does not change total net assets and has no impact on its consolidated financial results.
Takeda Pharmaceutical Company Limited and its subsidiary Takeda Vaccines, Inc. reported disposal of all their HilleVax, Inc. (HLVX) common stock held through Takeda Vaccines. On 09/17/2025, 6,724,000 shares were sold pursuant to a cash tender offer by XOMA Royalty Corporation and XRA 4 Corp. at a price of $1.95 per share, with closing announced on 09/17/2025.
The filing states that following the transaction the reporting persons hold 0 shares beneficially. The shares were held directly by Takeda Vaccines, Inc., an indirect wholly owned subsidiary of Takeda Pharmaceutical Company Limited, and the filing explains the ownership chain among Takeda entities.
HilleVax, Inc. (HLVX) agreed to be acquired and taken private by XOMA Royalty Corporation through a cash tender offer and subsequent merger. Shareholders received $1.95 per share plus one non-transferable contractual contingent value right (CVR) for each share. The tender offer expired and was completed on September 15, 2025, and the merger became effective September 17, 2025, with Merger Sub merging into HilleVax and HilleVax continuing as the surviving corporation and a wholly owned subsidiary of Parent. As a result, HilleVax common stock ceased to be publicly traded, Nasdaq delisting and deregistration steps were requested, and the company plans to suspend Exchange Act reporting by filing Form 15.
Takeda reported positive Phase 3 results for oveporexton (TAK-861), an oral OX2R-selective agonist for narcolepsy type 1 (NT1). Two global, double-blind, placebo-controlled studies (FirstLight and RadiantLight) met all primary and secondary endpoints at week 12 with p-values <0.001 across doses (twice-daily 1mg and 2mg), showing statistically significant improvement in wakefulness, excessive daytime sleepiness, cataplexy frequency, symptom severity and quality of life.
The 12-week program enrolled 273 patients across 19 countries; more than 95% of completers entered the ongoing long-term extension. Oveporexton was generally well tolerated with no treatment-related serious adverse events reported; the most common adverse events were insomnia and urinary urgency/frequency. Takeda said these Phase 3 results do not have a significant impact on its consolidated forecast for the fiscal year ending March 31, 2026.
Takeda Pharmaceutical Company Limited (NYSE: TAK) has filed a Form 144 indicating the planned sale of 52,649 American Depositary Shares (ADSs) through Interactive Brokers.
- Aggregate market value: US$811,847.58
- Percentage of shares outstanding: ~0.04% of the company’s 123,490,548 ADSs outstanding
- Approximate sale date: 09 July 2025
- Security class: American Depositary Shares listed on the NYSE
- Acquisition source: The shares derive from restricted stock unit (RSU) awards that vested on 01 July 2025
- No prior sales were reported by the same holder during the preceding three-month period
The filing does not disclose the name of the selling shareholder, but Rule 144 requires that the seller affirm they possess no undisclosed material adverse information regarding Takeda. Because the volume represents a very small fraction of total outstanding ADSs, the transaction is unlikely to exert material pressure on the stock price. Nevertheless, investors often monitor Form 144 notices as early signals of insider disposition activity and potential sentiment shifts.
Takeda Pharmaceutical Company Limited (NYSE: TAK) has filed a Form 144, indicating the intent to sell up to 102,972 American Depositary Shares (ADSs) on or about 07 July 2025 through broker Interactive Brokers LLC. The proposed sale represents roughly 0.08 % of the company’s 123,490,548 ADSs outstanding and carries an aggregate market value of $1,587,828.24 (≈ $15.42 per ADS, calculated from the filing’s data).
The shares were acquired via restricted stock unit (RSU) awards that vested on 01 July 2025; no cash purchase was involved as the compensation-based grant constituted the consideration. The filer reports no prior sales during the past three months. According to Rule 144 requirements, the signer attests to possessing no undisclosed material adverse information and affirms compliance with Rule 10b5-1, if applicable.
While Form 144s do not guarantee that a transaction will occur, they give investors advance notice of potential insider or affiliate sales that could incrementally add to market supply. In this case, the planned volume is relatively small compared with total float, suggesting a minimal direct impact on liquidity or price, though insider sales can sometimes influence sentiment.